natgillin/translations-raw huggingface dataset:
In the first normalization step the replicates of the same sample are normalized by calculating the mean presentation for each peptide in the respective replicate set. This mean is used to compute normalization factors for each peptide and LC-MS run. Averaging over all peptides results in run-wise normalization factors which are applied to all peptides of the particular LCMS run. 
(62) izračunavanje normalizacijskog čimbenika za svaki peptid i svaku repliciranu obradu uporabom navedenog prosječnog iznosa prisustva; (63) = izračunavanje prosjeka svih peptidnih rezultata u normalizacijskim čimbenicima prema obradi; (64) - primjenu normalizacijskih čimbenika prema obradi na sve peptide određene replicirane obrade.
applying to the hair a formulation comprising a binding agent of Formula I wherein 
(a) nanošenje na kosu formulacije koja sadrži sredstvo za vezanje formule I
The compound or composition for use according to claim 1, wherein the disease or disorder is bone cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je genitalno-urinarni Tak.
The modular antibody according to the invention is preferably conjugated to a label or reporter molecule, selected from the group consisting of organic molecules, enzyme labels, radioactive labels, colored labels, fluorescent labels, chromogenic labels, luminescent labels, haptens, digoxigenin, biotin, metal complexes, metals, colloidal gold and mixtures thereof. 
Modularno protutijelo prema zahtjevu 12, naznačeno time, da je protein koji je fuzioniran na modularno protutijelo, odabran iz skupine koja se sastoji od ostalih modularnih protutijela, imunoglobulina, liganda, strukturnih proteina, enzima i toksina.
Discharge device according to claim 11, wherein the first locking means comprises a first stop which defines said intermediate position and wherein the second locking means forms a second stop preventing movement of the valve element from the intermediate position into the first position due by a a biasing force of the spring, when the second locking means is locked. 
Naprava za pražnjenje prema bilo kojem prethodnom zahtjevu, naznačena time, da naprava za pražnjenje (1) obuhvaća drugo sredstvo za zabravljivanje koje sprečava pomicanje iz međupoložaja u prvi položaj, pri čemu ponajprije drugo sredstvo za zabravljivanje tvori drugi graničnik (22) koji sprečava pomicanje elementa ventila (5) iz međupoložaja u prvi položaj zbog sile prenaprezanja kad je drugo sredstvo za zabravljivanje zabravljeno.
a stage for calculating dynamically a target state of charge, SOCtar(t), of an energy storage system required to support the worst possible fluctuation; and 
stadij dinamičkog izračuna ciljanog stanja naboja, SOC,,(t), potrebnog sustavu za skladištenje energije za podržavanje najlošije moguće fluktuacije; i .
Still more preferably, the amino acid sequence of (a) of the chimera of the invention is SEQ ID NO: 1. 
DNK polimeraza himera prema zahtjevu 8, gdje 029 tip DNK polimeraza od (a) ima lanac amino kiseline SEQ ID NO: 1.
The method of claim 1, wherein sorbitol is present in the G-CSF composition in the range of from 10 to 100 mg/ml. 
Postupak prema bilo kojem zahtjevu od 1 do 4, naznačen time, da je količina sorbitola u G-CSF-sastavu, u rasponu od 10 do 100 mg/ml, poželjno od 25 do 75 mg/ml.
A crystal of ethyl 3-(4-carboxy-2,6-dichlorophenyl)-2-methyl methacrylate having a diffraction angle 2θ of a main peak of powder X-ray diffraction of 8.1, 16.3, 19.2, 20.0, 24.8 and 39.0 degrees. An optically active compound represented by the formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof as a platelet production regulating agent. 
Kristal etil 3-(4-karboksi-2,6-diklorofenil)-2-metilakrilata naznačen time da ima glavni vršak kod difrakcije X- zraka na prahu s kutom difrakcije 20 kod 8.1, 16.3, 19.2, 20.0, 24.8, 1 39.0 stupnjeva, pri čemu su uvjeti mjerenja difrakcije X-zraka kako slijedi: vakuumska cijev CuK a-zraka, napon rendgenske cijevi 40kV, struja rendgenske cijevi 40mA ili SOmA.
The method of claim 1, wherein the parent virus is a poliovirus, rhinovirus, influenza virus, severe acute respiratory syndrome (SARS) coronavirus, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), infectious bronchitis virus, Ebolavirus, Marburg virus, dengue fever virus, West Nile disease virus, Epstein-Barr virus (EBV), yellow fever virus, Poxvirus, Herpes virus, Papillomavirus, or Adenovirus. 
Oslabljeni virus prema zahtjevu 1., naznačen time što je virus poliovirus, rinovirus, virus influence, teški akutni respiratorni sindrom (SARS), koronavirus, virus humane imunodeficijencije (HIV), virus hepatitisa € (HCV), virus infektivnog bronhitisa, virus Ebole, virus Marburg, virus denga groznice, virus groznice Zapadnog Nila, Epstein-Barr virus (EBV), ili virus žute groznice.
The method according to claim 5, wherein the mixed liquid injected into the first tank is adjusted to a viscosity of 3,000 cPs to 7,000 cPs, and a pressure of 0.1 kg/cm2 to 3 kg/cm2 is applied to the air inlet of the first tank. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se miješana tekućina ubrizgavana u prvi spremnik podešava do viskoznosti od 3000 cPs do 7000 cPs, a ulaz zraka prvog spremnika se podvrgava tlaku od 0,1 kg/cm2 to 3 kg/cm2.
X5-X8 are independently selected from the group consisting of N, C and S, wherein at least one X must be N or S; 
do X8 su neovisno odabrani iz skupine koju čine N, C i S, pri čemu najmanje jedan X mora biti N ili S;
The connector pin assembly (16) of Claim 1 further comprising: cooperatively engageable abutment structures carried by said longitudinally central portion of said connector pin member (34) and said hollow body and being operable to limit the total amount of relative rotation between said connector pin member (34) and said hollow body. 
kooperativno surađujuće granične strukture nošene od strane navedenog uzdužnog centralnog dijela navedenog elementa (34) spojnog klina i navedenog šupljeg tijela koje se mogu koristiti da bi se ograničila ukupna količina relativne rotacije između navedenog elementa (34) spojnog klina i navedenog šupljeg tijela.
wherein a periphery of the hot-side heat spreader mechanically contacts the wall of the SAS structure at the first open side, and a periphery of the cold-side heat spreader mechanically contacts the wall of the SAS structure at the second open side such that a compression force applied to the heat pump is absorbed by the SAS structure. 
pri čemu rubni dio toplinskog raspršivača koji predaje toplinu, mehanički dotiče zid od SAS-konstrukcije uz prvu otvorenu stranu, a rubni dio toplinskog raspršivača koji preuzima toplinu, mehanički dotiče zid od SAS-konstrukcije uz drugu otvorenu stranu, tako da se tlačna sila koja se primjenjuje na toplinsku pumpu, apsorbira putem SAS-konstrukcije.
a chamber; a compression spring; and 
- < kompresijsku oprugu (24), i
The method according to embodiment 50, wherein the a-synuclein-related disorder is selected from the group consisting of Parkinson's disease, dementia with Lewy bodies and/or Lewy neurites, Alzheimer's disease, Down's syndrome, Multiple Systemic Atrophy (MSA), other diseases with Lewy body pathology, Alzheimer's disease syndrome, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, prion disease, Creutzfeldt Jakob's disease, Gerstmann-Sträussler-Scheinker syndrome, kuru, fatal familial insomnia, cerebrovascular amyloidosis, glaucoma, age-related macular degeneration, psychiatric syndromes, schizophrenia and schizophrenia-like disorders. 
Postupak proizvodnje antitijela za odgađanje početka ili za liječenje poremećaja vezanog uz a-sinuklein kod pojedinca, pri čemu je poremećaj vezan uz a-sinuklein odabran iz skupine koja se sastoji od Parkinsonove bolesti, demencije s Lewyjevim tjelešcima i/ili Lewyjevih neuritima, Alzheimerove bolesti, Downovog sindroma, multiple sistemske atrofije (MSA), drugih bolesti s patologijom Lewyjevih tjelešaca, sindroma Alzheimerove bolesti, amiotrofične lateralne skleroze, frontotemporalne demencije, Huntingtonove bolesti, prionske bolesti, Creutzfeldt Jakobove bolesti, Gerstmann-Straussler-Scheinker sindroma, kuru, fatalne familijalne nesanice, cerebrovaskularne
The method according to claim 1, wherein after one month of receiving at least one administration of collagenase, the patient achieves an active external rotation of greater than 15°, as compared to baseline. 
Uporaba prema bilo kojem od zahtjeva 1 do 3, naznačena time da nakon jednog mjeseca primanja najmanje jednog davanja kolagenaze, pacijent postiže aktivnu vanjsku rotaciju veću od 15%, u usporedbi s početnim stanjem.
Item 12. The method according to Item 1, wherein the organic chemical is at least one member selected from the group consisting of o-chlorophenol, p-chlorophenol, 2,4-dichlorophenol, p-tert-butylphenol, 1-naphthol, 3,5-xylenol, carbendazim, 17B-estradiol and bisphenol A. 
Postupak prema zahtjevu 1, naznačen time, da organska kemikalija je barem jedan član odabran iz skupine koja se sastoji od sljedećih: o-klorofenol, p-klorofenol, 2,4-diklorofenol, p-tert-butilfenol, 1-naftol, 3,5-ksilenol, karbendazim, 17fB-estradiol i bisfenol A.
The pharmaceutical composition according to claim 5, wherein the other anti-HCV agent is an immunomodulatory agent selected from a-, B-, δ-Y-, t- and w-interferon and pegylated forms thereof. 
Farmaceutski sastav prema zahtjevu 15, naznačen time, da je sljedeće anti-HCV-sredstvo jedno imunomodulacijsko sredstvo odabrano od ae, 3-, 8-Y-, T- i o-interferona te od njihovih pegiliranih oblika.
A compound having the formula: or a pharmaceutically acceptable salt thereof. 
Spoj naznačen time da ima formulu: Ba < ili njegova farmaceutski prihvatljiva sol.
The composition of claim 1, wherein the dispersant is a nonionic surfactant and/or an anionic surfactant. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je sredstvo za disperziranje neionski surfaktant i / ili anionski surfaktant.
In use, the container or canister may be placed on the base, pressure is applied to the container or canister thereby activating the motor means and agitating the contents of the container or canister. 
Pri uporabi se posuda ili spremnik može postaviti na postolje, posuda ili spremnik se pritisne kako bi se pokrenuo motor i miješanje sastojaka u posudi ili spremniku.
The botulinum toxin for use according to any one of the first to sixth embodiments, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C1, D, E, F, G, and mixtures thereof, is provided in a seventh embodiment. 
7. > Botulinski toksin namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se botulinski toksin bira iz skupine koju čine tipovi A, B, Ci, D, E, F, G botulinskog toksina, te njihove smjese.
a phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, or triazinyl ring substituted by one occurrence of W at the meta or para position of the ring; or 
fenil, piridil, pirimidil, pirazinil, piridazinil ili piridazinil prsten supstituiran jednom sa W na meta ili para položaju prstena; ili
Longitudinal grooves represent long-lasting conditions that can occur physiologically as shallow and delicate furrows, usually parallel and separated by low, projecting ridges. 
Longitudinlni utori predstavljaju dugotrajna stanja koja se mogu pojaviti fiziološki kao plitke i delikatne brazde, obično paralelne i odvojene niskim grebenima.
The shelf according to claim 6, wherein a second portion of the strip closes off an end of the channel or girder of the plate. 
Polica (10) sukladno patentnom zahtjevu 4, pri čemu taj dio (25) trake (21) zatvara kraj takvog kanala ili nosača (13).
The mixture was filtered through Celite, the Celite pad was washed with ethanol, and the solution was concentrated in vacuo until the total volume was approximately 50 mL. 
Smjesa se filtrira kroz Celit. Celitni sloj se ispere etanolom, i otopina se koncentrira uz podtlak dok ukupni volumen ne bude oko 50 mL.
to 98 % (w/w) of a monofunctional acrylate or methacrylate monomer of formula [1]: wherein 
C) 70 do 98 % (težinski) monofunkcionalnog akrilatnog ili metakrilatnog monomera formule [1]: gdje
A compound as claimed in claim 11, for use in treating chronic low back pain or osteoarthritis. 
Spoj u skladu s patentnim zahtjevom 27, naznačen time, da se koristi za liječenje kronične križobolje ili osteoartritisa.
A composition for use according to claim 1, wherein the reduction ranges from 143 ml to 358 ml. 
Pripravak naznačen time da je za uporabu prema zahtjevu 8 u postupku koji sadrži:
Process as claimed in claim 7, wherein the reinforcing material is a nonwoven polyester. 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da je materijal za pojačavanje netkani poliester.
Then the product was granulated through a sieve of 3x3 mm (in process control, loss on drying (LOD) 21.4 %). 
Produkt je nakon toga granuliran kroz sito dimenzija 3 x 3 mm (u kontroliranom postupku, gubitak tijekom sušenja LOD 21,4 %).
Currently, the oral therapy of intestinal infections, and in particular colon infections, uses substances having antibacterial activity which must have specific characteristics such as: broad spectrum of activity on Gram+ and Gram− bacteria, resistance to strongly acidic environments, such as the gastric environment, anti-infectious activity independent of the presence of the intestinal biomass, residence inside the intestine for an appropriate period of time, good penetrability into the infecting host cell and good tolerability (Braga P C. Interaction of antibiotics on enteric microflora. 
Trenutno se za oralno liječenje crijevnih infekcija, posebno infekcija kolona, koriste tvari antibakterijskog djelovanja specifičnih karakteristika kao što su: široki spektar djelovanja na Gram+ i Gram- bakterije, otpornost na uvjete jake kiselosti kao što su uvjeti u gastričkom okolišu, antiinfektivno djelovanje neovisno o prisustvu crijevnih biomasa, ostajanje unutar crijeva kroz odgovarajući period vremena, dobra penetrabilnost u inficiranu stanicu domaćina 1 dobra tolerancija (Braga PC. Interaction of antibiotics on enteric microflora.
After cooling water (88 ml) was added to the reaction mixture and the resulting solution extracted with ether (576 ml). 
Nakon hlađenja, u reakcijsku smjesu se doda voda (88 ml) i rezultirajuća otopina se ekstrahira eterom (576 ml).
For example an alkylthio group may be oxidised to an alkylsulfinyl or alkylsulfonyl group, a cyano group reduced to an amino group, a nitro group reduced to an amino group, a hydroxy group alkylated to a methoxy group, a bromo group converted to an alkylthio group, an amino group may be acylated to give an alkanoylamino group (for example by reaction with a suitable acid chloride or acid anhydride) or an alkanoyloxy group may be hydrolysed to a hydroxy group (for example an acetyloxyacetyl group may be converted to a hydroxyacetyl group). 
Na primjer, alkiltio skupina može biti oksidirana u alkinilsulfinil ili alkilsulfonil skupinu, cijano skupina može biti reducirana u amino skupinu, nitro skupina može biti reducirana u amino skupinu, hidroksi skupina može biti alkilirana u metoksi skupinu, bromo skupina može biti konvertirana u alkiltio skupinu, amino skupina može biti acilirana do alkanoilamino skupine (na primjer u reakciji sa odgovarajućim kiselinskim kloridom ili anhidridom kiselina) ili se alkanoiloksi skupina može hidrolizirati do hidroksi skupine (na primjer, acetiloksiacetil skupine može biti konvertirana u hidroksiacetilnu skupinu).
The AvPAL variant of claim 17, wherein at least 28 percent of lysine residues at positions 2, 10, 32, 145, 195, 301, 413, 493, and 522 of the AvPAL variant are pegylated; wherein at least 51 percent of lysine residues at positions 2, 10, 195, 413, 493, and 522 of the AvPAL variant are pegylated; or wherein at least 75 percent of lysine residues at positions 2, 10, 195, 493, and 522 of the AvPAL variant are pegylated. 
AVvPAL varijanta u skladu s patentnim zahtjevom 17, naznačena time, da je barem 28 & lizinskih ostataka na položajima 2, 10, 32, 145, 195, 301, 413, 493 te 522 AvPAL varijante pegilirano, pri čemu je barem 51 % lizinskih ostataka pegilirano na položajima 2, 10, 195, 413, 493 te 522 AvPAL varijante ili pri čemu je najmanje 75 % lizinskih ostataka pegilirano na položajima 2, 10, 195, 493 1 522 AvPAL varijante.
General Description of Compounds of the Invention 
Datum objave europskog patenta:
The DNA of claim 3, which comprises the polynucleotide having the nucleotide sequence of SEQ ID NO: 11 encoding the amino acid sequence of SEQ ID NO: 1, the polynucleotide having the nucleotide sequence of SEQ ID NO: 12 encoding the amino acid sequence of SEQ ID NO: 2, and the polynucleotide having the nucleotide sequence of SEQ ID NO: 13 encoding the amino acid sequence of SEQ ID NO: 3; and which comprises the polynucleotide having the nucleotide sequence of SEQ ID NO: 15 encoding the amino acid sequence of SEQ ID NO: 4; the polynucleotide having the nucleotide sequence of SEQ ID NO: 16 encoding the amino acid sequence of SEQ ID NO: 5; and the polynucleotide having the nucleotide sequence of SEQ ID NO: 17 encoding the amino acid sequence of SEQ ID NO: 6. 
DNA u skladu s patentnim zahtjevom 3, naznačena time što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 11, koji kodira aminokiselinski slijed sa SEQ ID NO: 1, polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 12, koji kodira aminokiselinski slijed sa SEQ ID NO: 2, te polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 13, koji kodira aminokiselinski slijed sa SEQ ID NO: 3; te što sadrži polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 15, koji kodira aminokiselinski slijed sa SEQ ID NO: 4; polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 16, koji kodira aminokiselinski slijed sa SEQ ID NO: 5; te polinukleotid koji ima nukleotidni slijed sa SEQ ID NO: 17, koji kodira aminokiselinski slijed sa SEQ ID NO: 6.
The receiver according to claim 1, wherein the holder comprises channels located along the interior wall of the receiver. 
Prijemna posuda sukladno patentnom zahtjevu 5 naznačena time što taj držač indikatora sadrži kanale koji se nalaze duž unutarnje stijenke te prijemne posude.
A virosomal preparation comprising influenza hemagglutinin (HA) antigen wherein the preparation does not contain an additional adjuvant, for use as an intradermal influenza vaccine in human subjects. 
Virosomni pripravak koji sadrži antigen influenca hemaglutinina (HA) pri čemu pripravak ne sadrži dodatni adjuvant, naznačen time da je za uporabu kao intradermalno cjepivo protiv influence kod čovjeka kao subjekta.
Cosmetic use according to any one of Claims 6 to 9, characterised in that the said hydrating agent is selected from the group comprising urea, allantoin, hyaluronic acid and its derivatives, glycerine, amino acids, acetyl monoethanolamide, butoxypropanol, butyl glycol, low molecular weight polyethylene glycols, aloe, mallow and sorbitol. 
Kozmetička upotreba prema bilo kojem zahtjevu od 6 do 9, naznačena time da se navedeno hidratantno sredstvo bira iz skupine koja sadrži ureu, alantoin, hijaluronska kiselinu i njene derivate, glicerin, aminokiseline, acetil monoetanolamid, butoksipropanol, butil glikole, polietilen glikole male molekularne mase, aloe, sljez i sorbitol.
Use of an amount of an opioid antagonist in an amount at least sufficient to substantially antagonize a therapeutic amount of opioid agonist, when both, the opioid agonist and the opioid antagonist, are administered intravenous at the same time, in the form of a controlled release dosage form comprising a homogeneous controlled release matrix formulation comprising a hydrophobic material, including at least one hydrophobic polymer, wherein the hydrophobic polymer is ethyl cellulose, and at least one fatty alcohol or fatty acid selected from C12 to C36 aliphatic alcohols or acids, and said therapeutic amount of an opioid agonist and said sufficient amount of opioid antagonist, to prevent the formation of an extract of said controlled release matrix formulation comprising the opioid agonist by a one step extraction procedure comprising the steps of: 
Uporaba količine opioidnog antagonista koja je dovoljna da barem bitno djeluje antagonistički na terapijsku količinu opioidnog agonista kada se oba, opioidni agonist 1 opioidni antagonist, daju istodobno intravenski kao dozirni oblik s kontroliranim oslobađanjem koji sadrži homogenu formulaciju matriksa s kontroliranim oslobađanjem, a koja sadrži hidrofobni materijal, uključujući barem jedan hidrofobni polimer, gdje je hidrofobni polimer etil celuloza i barem jedan masni alkohol ili masnu kiselinu izabrane između C;> do C34 alifatskih alkohola ili kiselina, i terapijsku količinu opioidnog agonista i dovoljnu količinu opioidnog antagonista, da se spriječi nastanak ekstrakta formulacije matriksa s kontroliranim oslobađanjem koja sadrži opioidni agonist pomoću postupka ekstrakcije u jednom koraku, a postupak obuhvaća korake:
In a potential embodiment, the air scenting device according to the present disclosure may exhibit the alternative or additional feature that the housing comprises a plurality of accommodations, and each of the accommodations is configured to accommodate at least one scent module. 
Sklop u skladu sa bilo kojim ili više od jednog od prethodnih patentnih zahtjeva, gdje navedeno kućište sadrži više prijemnih dijelova, i svaki od navedenih prijemnih dijelova je konfiguriran da primi najmanje jedan mirisni modul.
Cocoa-derived material according to any of claims 1 to 8, wherein said soluble cocoa powder comprises between 1 and 24wt% by fat-free dry weight of polyphenols. 
Tvar dobivena iz kakaa u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time, da dotični topljiv prašak kakaa sadrži maseni udjel polifenola u rasponu od 1 do 24 % u suhom, odmašćenom stanju.
in step (a) the aqueous solution of a calcium salt and the solution of a zofenopril salt in an organic, water miscible solvent are combined in a water: organic solvent ratio of 1:1 to 1:10; and/or 
(1) u koraku (a) vodena otopina kalcijeve soli i otopina zofenopril soli u organskom otapalu koji se miješa sa vodom su kombinirani u odnosu voda: organsko otapalo od 1:1 do 1:10; i/ili
A process for preparing a compound according to claim 1, said process comprising: reacting an intermediate of formula (II) wherein M represents hydrogen or an alkali metal, with a compound of formula (III), in the presence of a base: 
Postupak priprave spoja prema zahtjevu 1, naznačen time da se provodi reakcija međuspojeva formule (II) pri čemu M predstavlja vodik ili alkalni metal, sa spojem formule (III), uz prisutstvo baze: mae zm o
Microparticles according to claim 3 wherein the polymer matrix comprises a Resomer® RG polymer and a star polylactide-co-glycolide polymer having a weight average molecular weight of about 50,000 Da. 
Mikročestice u skladu sa zahtjevom 2, naznačene time, da polimerni matriks sadrži Resomer® RG polimer i zvjezdasti polilaktid-ko-glikolid polimer koji ima težinsku prosječnu molekularnu masu od oko 50.000 Da.
combining the by-product first steam flow (118) and the second steam flow (106), wherein the steam flows are combined after the by-product first steam flow is processed through the heat recovery steam generator; routing the combined steam flow (120) through a steam turbine generator (124); 
kombiniranjem prve struje pare (118) kao nusproizvoda i druge struje pare (106), pri čemu se struje pare kombiniraju poslije prerade prve struje pare kao nusproizvoda uz pomoć generatora pare s rekuperacijom topline;
The composition of claim 10, wherein the buffer is selected from the group consisting of monobasic potassium phosphate and tribasic potassium phosphate, BIS-TRIS, BIS-TRIS Propane, HEPES, HEPES sodium salt, MES, MES Sodium salt, MOPS, MOPS Sodium Salt, Sodium salt, and Sodium Phosphate Buffer. 
Postupak prema zahtjevu 10, naznačen time da pufer je odabran iz skupine koja sadrži monobazični kalijev fosfat i trobazični kalijev fosfat, BIS-TRIS, BIS-TRIS Propan, HEPES, HEPES natrijevu sol, MES, MES natrijevu sol, MOPS, MOPS natrijevu sol, natrijevu sol, te natrijev fosfatni pufer.